Journal club

Journal club: SURMOUNT-1, read without the press release Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on SURMOUNT-1. It is mine, it is…

Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field — setting out what I have, and where I think it stops being reliable. Collecting what is known about SURMOUNT-OSA in one place,…

Journal club: SURPASS-2 and the semaglutide 1 mg comparator Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it…

Journal club: orforglipron phase 2 and the non-peptide question Writing it up because I had to work it out twice and would rather nobody else did. Orforglipron phase 2, and specifically the version of it that…

On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. Reading SUSTAIN 6 ( N Engl J Med , 2016) for the population rather than the effect,…

On the subject in the title: Journal club: what we got wrong in an earlier session Working notes rather than a conclusion. Bringing a claim rather than a paper, because the claim is the thing circulating. The…

Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Working notes on STEP 1 rather than a conclusion. I would rather…

Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Writing it up because I had to work it out twice and would rather nobody else did. The question about STEP 4 that I actually want…

Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about what the numbers mean rather than what…

Journal club: is percentage weight change the right endpoint? I have a specific reason for asking rather than idle curiosity, and the context is below. Bringing a claim rather than a paper, because the claim…

Journal club: indirect comparison between two programmes, defended and attacked Writing it up because I had to work it out twice and would rather nobody else did. Trying to work out what would count as…

Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of LEADER is wrong? I ask because I have…

On the subject in the title: Journal club: SURPASS-2 and the semaglutide 1 mg comparator Working notes rather than a conclusion. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before posting;…

Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. A follow-up question about orforglipron phase 2 that I…

On the subject in the title: Journal club: FLOW and the renal composite, component by component Working notes rather than a conclusion. Reading FLOW ( N Engl J Med , 2024) for the population rather than the…

Journal club: STEP 4 and what a withdrawal design can prove — one year on Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 4 ( JAMA , 2021). Please read…

Journal club: the CagriSema phase 2 combination paper — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on CagriSema phase 2 combination paper.…

Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Two things I would like separated before anyone answers on…

On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…

Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Working notes on STEP 1 rather than a conclusion. I would rather…

The question in the title: Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? I will give what I have already checked below so nobody repeats it. Reading SUSTAIN 6 ( N Engl J Med ,…

Posting this under the heading it deserves: Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Everything below is what sits behind that. Posting a small dataset on SURMOUNT-4 and…

On the subject in the title: Revisiting: Journal club: SURMOUNT-1, read without the press release Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it…

Journal club: SURMOUNT-4 and continuation versus withdrawal — setting out what I have, and where I think it stops being reliable. Trying to establish the boundary conditions on SURMOUNT-4 and continuation…

Journal club: PIONEER 6 as a safety trial Writing it up because I had to work it out twice and would rather nobody else did. Bringing a claim rather than a paper, because the claim is the thing circulating.…

Posting this under the heading it deserves: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Everything below is what sits behind that. Collecting what is known about SURMOUNT-OSA in one place,…

Posting this under the heading it deserves: Journal club: indirect comparison between two programmes, defended and attacked — one year on Everything below is what sits behind that. Asking about indirect…

Journal club: how we handle discontinuation in obesity trials — what changed since — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it…

Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…

Posting this under the heading it deserves: Journal club: semaglutide in MASH, and surrogate endpoints Everything below is what sits behind that. Working notes on semaglutide in MASH rather than a conclusion.…